Clinical Trials Browser

Phase 2 × NETWORK × pembrolizumab × Clear all

NCT03516279 2026-03-02

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase, Neoplasm, Residual

NCT05180097 2026-02-02

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Phase 2 Recruiting

Hodgkin Disease

NCT05563558 2024-06-11

PEAPOD_FOS

Phase 2 Recruiting

Prostate Cancer Metastatic

NCT02580994 2023-12-11

REACTION

Phase 2 Completed

Small Cell Lung Carcinoma

NCT03260712 2023-11-03

Pembrolizumab in Biliary Tract Cancer

Phase 2 Completed

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Neoplasm Metastasis

NCT02740920 2023-08-25

Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker

Phase 2 Terminated

9 enrolled 8 charts

Melanoma